Core Viewpoint - The company expects to achieve a net profit attributable to shareholders of 7.5 million to 11 million yuan in 2025, marking a turnaround from losses in the previous year, although the net profit after deducting non-recurring gains and losses is projected to be a loss of 14 million to 10 million yuan [1] Group 1: Financial Performance - The company's health business revenue is expected to grow by approximately 15.5% compared to the previous year [1] - The estimated impairment losses on various assets are expected to decrease by approximately 78.76 million yuan compared to the previous year [1] - The company's net cash flow from operating activities is projected to be around 87 million yuan, an increase of approximately 4.7 million yuan from the previous year [1] Group 2: Business Challenges - The tile business is facing intensified market competition, leading to a year-on-year decline in sales volume of approximately 6% and a year-on-year decrease in sales revenue of about 15.7% [1] - The decline in sales revenue from the tile business is expected to result in a reduction of approximately 41 million yuan in four types of expenses compared to the previous year [1] - The estimated income tax expense is expected to decrease by approximately 33.89 million yuan compared to the previous year [1]

Group 1 - The company Yueshen Health expects a net profit attributable to shareholders of 7.5 million to 11 million yuan for 2025, representing a year-on-year growth of 105.10% to 107.48% [1] - The main reason for the performance change is a 15.5% increase in revenue from the health business compared to the previous year [1] - The company anticipates a reduction of approximately 78.76 million yuan in various asset impairment losses compared to the previous year [1] Group 2 - The company's tile business experienced a 6% year-on-year decline in sales volume and a 15.7% decrease in sales revenue due to intensified market competition [1] - As a result of the decline in tile business revenue, the company expects a reduction of approximately 41 million yuan in four expense categories compared to the previous year [1] - The company also projects a decrease of approximately 33.89 million yuan in income tax expenses compared to the previous year [1]

证券代码：002162 证券简称：悦心健康 公告编号：2026-003 上海悦心健康集团股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于扭亏为盈情形 三、业绩变动原因说明 2025 年预计公司归属于上市公司股东的净利润较上年扭亏为盈，盈利约 750 万元至 1,100 万元。主要系： 1、本报告期大健康业务收入较上年增长约 15.5%。 2、本报告期各类资产减值损失预计比上年减少约 7,876 万元。 3、本报告期瓷砖业务受市场竞争加剧影响销售量同比下降约 6%，销售收入同比下降 约 15.7%，受瓷砖业务销售收入下降影响，四项费用比上年下降约 4,100 万元。 4、本报告期所得税费用预计比上年减少约 3,389 万元。 5、本报告期经营活动产生的现金流量净额约 8,700 万元，比上年增加约 470 万元。 单位：万元 | 项 目 | 本报告期 | | | | 上年同期 | ...

证券日报网讯 1月23日，悦心健康在互动平台回答投资者提问时表示，温州东方悦心中等职业技术学校 的第一届学生目前仍处于在校学习阶段，将于今年6月毕业。待其毕业后，公司将优先推荐优秀毕业生 到公司参与运营管理的相关康养项目（包括温州市龙湾区康养福利中心项目）相关岗位，实现"人才培 养与产业需求"的无缝对接。未来，随着项目的深入推进，学校将持续深化与项目的合作，为学生提供 更多实习就业机会，助力康养产业发展。 （文章来源：证券日报） ...

Group 1 - The core point of the article is that Yueshen Health (002162) has disclosed its shareholder information, indicating a total of 55,684 shareholders as of January 20, 2026, with 3,627 of them being institutional investors [1] Group 2 - The total number of shareholders for Yueshen Health is 55,684 [1] - The number of institutional shareholders is 3,627 [1]

上海悦心健康集团股份有限公司 关于 2026 年度日常关联交易预计公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 1、上海悦心健康集团股份有限公司（以下简称"公司"）于 2026 年 1 月 22 日召开第 八届董事会第十九次会议，审议通过了《关于 2026 年度日常关联交易预计的议案》。 公司结合与关联人 2025 年度日常关联交易实际执行情况及未来经营发展需要， 对 2026 年度公司与关联人发生的日常性关联交易进行了预计，具体如下表： | 关联交易类别 | 2026 年度预计金额 | 2025 年度同类交易实际发生金额 | | --- | --- | --- | | | （万元） | （万元） | | 向关联人销售产品 | 106.00 | 6.78 | | 向关联人提供管理咨询服务 | 815.96 | 829.36 | | 向关联人采购商品 | 6.00 | 6.10 | | 接受关联人委托代为销售其产品 | 1,800.00 | 0.00 | | 向关联人租入资产 | 1,239.51 | 913. ...

Group 1 - The company,悦心健康, announced that its eighth board meeting will be held on January 22, 2026, in Shanghai, combining in-person and communication methods [1] - The meeting will review the proposal regarding the expected daily related transactions for the year 2026 [1]

证券代码：002162 证券简称：悦心健康 公告编号：2026-001 上海悦心健康集团股份有限公司 第八届董事会第十九次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 一、董事会会议召开情况 上海悦心健康集团股份有限公司（以下简称"公司"）第八届董事会第十九次会议 于 2026 年 1 月 15 日以电子邮件的方式发出通知，会议于 2026 年 1 月 22 日在上海市闵 行区浦江镇恒南路 1288 号会议室以现场结合通讯方式召开。 会议由董事长李慈雄先生主持，应出席会议的董事 9 人，实际出席会议的董事 9 人， 公司部分高级管理人员列席了会议。本次会议的通知、召集和召开符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的规定，合法有效。 二、董事会会议审议情况 经审议表决，会议形成如下决议： 审议通过《关于 2026 年度日常关联交易预计的议案》； 公司董事李慈雄、余璟、宋源诚、陈超因在交易对方或在控制交易对方的法人单位 担任董事职务而对该议案予以回避表决。 该议案在提交董事会前，已经公司董事会独立董事专门会议审议，独立董事一致同 ...

Core Viewpoint - The renovation and building materials sector experienced growth, closing at 17,486.43 points with a rise of 1.30% [1] Group 1: Stock Performance - Kangxin New Materials led the sector with a closing price of 4.72 CNY per share, increasing by 10.02% [1] - Sankeshu followed with a closing price of 48.38 CNY per share, also rising by 10.00% [1] - Gujia Home Furnishing closed at 33.80 CNY per share, with a rise of 7.81% [1] - Meike Home Furnishing saw a decline, closing at 2.86 CNY per share, down by 8.33% [1] - Xiong Plastic Technology closed at 10.70 CNY per share, decreasing by 4.12% [1] - Yuexin Health closed at 5.08 CNY per share, down by 2.68% [1] Group 2: Market Outlook - Huafu Securities indicated that the supply-side reform expectations and the acceleration of anti-involution may signal a turning point in the building materials capacity cycle [1] - The expectation of declining interest rates is likely to restore home buying willingness, supported by storage and urban renewal initiatives [1] - The marginal recovery in home buying willingness and capacity is expected to increase the probability of stabilization in the real estate market fundamentals, which may also drive the recovery of post-real estate cycle demand [1]

Core Viewpoint - The continuous decline in the number of shareholders in various companies indicates a trend of increasing concentration of shares, with 102 companies experiencing a decrease for more than three consecutive periods, and some like Dazhongnan and Far East Transmission seeing declines for up to 12 periods [1][2]. Shareholder Trends - A total of 787 companies reported their latest shareholder numbers as of January 10, with significant declines noted in companies such as Dazhongnan (106,534 shareholders, down 29.73%) and Far East Transmission (64,541 shareholders, down 19.46%) [1]. - Companies with the largest recent declines in shareholder numbers include Hengshuai Co. (down 16.65%), Farantak (down 9.92%), and Furong Technology (down 7.34%) [1][3]. Market Performance - Among the companies with declining shareholder numbers, 57 saw their stock prices increase, while 43 experienced declines. Notable gainers include Hengshuai Co. (up 52.85%), Zhiguang Electric (up 44.75%), and Zhongyuan Neipei (up 33.24%) [2]. - 36 companies outperformed the Shanghai Composite Index, with Hengshuai Co. achieving a relative return of 47.37% compared to the index [2]. Industry Distribution - The industries with the highest concentration of companies experiencing declining shareholder numbers include basic chemicals (13 companies), electric equipment (10 companies), and electronics (8 companies) [2]. Institutional Activity - In the past month, 13 companies with declining shareholder numbers were subject to institutional research, with frequent inquiries directed at Xingfa Group, Jintian Co., and Hengxin Life, each receiving two rounds of institutional research [2]. - The companies with the most institutional participation include Xingfa Group (107 institutions), Caixun Co. (76 institutions), and Jintian Co. (23 institutions) [2]. Performance Forecasts - One company has released its preliminary earnings report for 2025, with Shaanxi Guotou A showing a net profit increase of 5.70%. Three companies have issued earnings forecasts, with the highest projected net profit growth being for Quan Feng Automobile, expected to be -315 million yuan, representing a year-on-year increase of 39.04% [3].